These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 23758587)

  • 1. Lack of long-term changes in circadian, locomotor, and cognitive functions in acute and chronic MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse models of Parkinson's disease.
    Fifel K; Dkhissi-Benyahya O; Cooper HM
    Chronobiol Int; 2013 Jul; 30(6):741-55. PubMed ID: 23758587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease.
    Castro AA; Wiemes BP; Matheus FC; Lapa FR; Viola GG; Santos AR; Tasca CI; Prediger RD
    Brain Res; 2013 Jun; 1513():103-16. PubMed ID: 23548600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Matheus FC; Aguiar AS; Castro AA; Villarinho JG; Ferreira J; Figueiredo CP; Walz R; Santos AR; Tasca CI; Prediger RD
    Behav Brain Res; 2012 Dec; 235(2):263-72. PubMed ID: 22921927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
    Leng A; Mura A; Hengerer B; Feldon J; Ferger B
    Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vigilance states in a parkinsonian model, the MPTP mouse.
    Monaca C; Laloux C; Jacquesson JM; Gelé P; Maréchal X; Bordet R; Destée A; Derambure P
    Eur J Neurosci; 2004 Nov; 20(9):2474-8. PubMed ID: 15525288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease.
    Prediger RD; Batista LC; Medeiros R; Pandolfo P; Florio JC; Takahashi RN
    Exp Neurol; 2006 Dec; 202(2):391-403. PubMed ID: 16908021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice.
    Yabuki Y; Ohizumi Y; Yokosuka A; Mimaki Y; Fukunaga K
    Neuroscience; 2014 Feb; 259():126-41. PubMed ID: 24316474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model.
    Kim NK; Choi BH; Huang X; Snyder BJ; Bukhari S; Kong TH; Park H; Park HC; Park SR; Ha Y
    Eur J Neurosci; 2009 Mar; 29(5):891-900. PubMed ID: 19245369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
    Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
    Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice.
    Shepherd KR; Lee ES; Schmued L; Jiao Y; Ali SF; Oriaku ET; Lamango NS; Soliman KF; Charlton CG
    Pharmacol Biochem Behav; 2006 Mar; 83(3):349-59. PubMed ID: 16580056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aging of the dopaminergic system and motor behavior in mice intoxicated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Schumm S; Sebban C; Cohen-Salmon C; Callebert J; Launay JM; Golmard JL; Boussicault L; Petropoulos I; Hild A; Rousselet E; Prigent A; Friguet B; Mariani J; Hirsch EC
    J Neurochem; 2012 Sep; 122(5):1032-46. PubMed ID: 22708926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease.
    Reksidler AB; Lima MM; Dombrowski P; Andersen ML; Zanata SM; Andreatini R; Tufik S; Vital MA
    J Neurosci Methods; 2008 Jan; 167(2):268-77. PubMed ID: 17931705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations.
    Ferro MM; Bellissimo MI; Anselmo-Franci JA; Angellucci ME; Canteras NS; Da Cunha C
    J Neurosci Methods; 2005 Oct; 148(1):78-87. PubMed ID: 15939479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of age-related dopaminergic neuron loss in the substantia nigra on the circadian rhythms of locomotor activity in mice.
    Tanaka M; Yamaguchi E; Takahashi M; Hashimura K; Shibata T; Nakamura W; Nakamura TJ
    Neurosci Res; 2012 Dec; 74(3-4):210-5. PubMed ID: 23044185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity of MPTP on neurotransmission in three mouse models of Parkinson's disease.
    Pain S; Gochard A; Bodard S; Gulhan Z; Prunier-Aesch C; Chalon S
    Exp Toxicol Pathol; 2013 Jul; 65(5):689-94. PubMed ID: 23083629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets.
    Iravani MM; Syed E; Jackson MJ; Johnston LC; Smith LA; Jenner P
    Eur J Neurosci; 2005 Feb; 21(4):841-54. PubMed ID: 15787691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
    Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW
    Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of dopamine disrupts circadian rhythms in a mouse model of Parkinson's disease.
    Fifel K; Cooper HM
    Neurobiol Dis; 2014 Nov; 71():359-69. PubMed ID: 25171792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.